About JFL LIFE SCIENCES
JFL LIFE SCIENCES is a publicly listed company based in Ahmedabad (India) founded in 2011 by Smiral Patel. General tablets, capsules, and dry powder injections are manufactured. The company has 6 employees. Its Indian entity Jfl Life Sciences Limited reported revenue of ₹131 Cr. JFL LIFE SCIENCES offers products and services including Dry Powder Injections and Tablets and Capsules. Its focus areas include Traditional Pharmaceuticals.
Company details
JFL Life Sciences was established in 2011 in Ahmedabad, India, within the life sciences sector. Pharmaceutical manufacturing operations are centered on general tablets, capsules, and dry powder injections. Production facilities are maintained in India to support these core activities. Leadership is provided by founder and director Smiral Patel, with focus placed on standard formulations for the industry.
- Headquarters Ahmedabad, India
- Employees 6
- Founders Smiral Patel
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website jfllifesciences.com
- Social LinkedIn
- Legal Name Jfl Life Sciences Limited
- Market Cap₹44.54 Cr
JFLLIFE-SM · NSE
- Share Price₹13.50
0.00% today
- Revenue₹131 Cr
FY 2025-26 · +60.1% YoY
- EBITDA₹11.71 Cr
Margin 8.9%
- Net Profit₹6.39 Cr
FY 2025-26 · +54.0% YoY
- P/E (TTM)4.7x
P/B 0.8x
- ROE15.0%
ROCE 18.2%
- Debt / Equity0.38
Interest cover 19.9x
- Employee Count6
Associated legal entities of JFL LIFE SCIENCES
JFL LIFE SCIENCES operates through Jfl Life Sciences Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Jfl Life Sciences Limited Listed CIN L24230GJ2010PLC060417 | Active | 25 Apr 2010 | Ahmedabad, Gujarat | ₹131 Cr | 8 | View details |
Products & Services of JFL LIFE SCIENCES
JFL LIFE SCIENCES offers a comprehensive portfolio of products and services, including Dry Powder Injections and Tablets and Capsules.
Dry Powder Injections are produced as part of the manufacturing process for pharmaceutical needs
Tablets and Capsules, including Beta Lactam and General types, are manufactured for distribution in various markets
Board of directors of Jfl Life Sciences Limited (JFL LIFE SCIENCES)
Jfl Life Sciences Limited is the primary company behind JFL LIFE SCIENCES. The board of Jfl Life Sciences Limited currently have 6 directors; the longest-serving is Sonu Lalitkumar Jain, appointed in 2022. 5 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Sonu Lalitkumar Jain DIN 09387661 | Director | 18 Jan 2022 | 4 yrs 9 mo | Jfl Life Sciences Limited |
| Smiral Ashwinkumar Patel DIN 00769486 | Managing Director | 18 Jan 2022 | 4 yrs 9 mo | Jfl Life Sciences Limited |
| Tejal Smiral Patel DIN 07391559 | Whole-time director | 18 Jan 2022 | 4 yrs 9 mo | Jfl Life Sciences Limited |
| Bhavna Basantbhai Shah DIN 09494548 | Director | 10 Feb 2022 | 4 yrs 9 mo | Jfl Life Sciences Limited |
| Manishkumar Jasvantlal Patel DIN 09499355 | Director | 10 Feb 2022 | 4 yrs 9 mo | Jfl Life Sciences Limited |
| Khyati Bhavya Shah DIN 09430457 | Director | 11 Aug 2025 | 1 yr 3 mo | Jfl Life Sciences Limited |
People of JFL LIFE SCIENCES
1 people are tracked at JFL LIFE SCIENCES (1 in leadership); the tracked headcount is 6.
| Name | Role | Group |
|---|---|---|
| Founder & Director | Leadership |
Complete people profiles for JFL LIFE SCIENCES
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of JFL LIFE SCIENCES
JFL LIFE SCIENCES is a publicly listed company on the NSE with ticker symbol JFLLIFE in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date08 Sep 2022
- Listed onNSE: JFLLIFE
- Listed entityJFL Life Sciences Limited
- Exchange sectorHealth technology
- ISININE0LA901015
- Share price₹10.75 · 2026-10-14
- Volume (last session)12,000
Financials of JFL LIFE SCIENCES
Exchange-reported figures of Jfl Life Sciences Limited, the listed company behind JFL LIFE SCIENCES (NSE: JFLLIFE-SM).
Financial Highlights
FY 2025-26 · StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 131 | 82.04 | 46.55 | 42.83 | 33.59 | 32.77 | 30.17 |
| Revenue growth | +60.1% | +76.2% | +8.7% | +27.5% | +2.5% | +8.6% | - |
| EBITDA | 11.71 | 8.19 | 4.55 | 3.93 | 5.36 | 2.16 | 1.87 |
| EBITDA margin | +8.9% | +10.0% | +9.8% | +9.2% | +16.0% | +6.6% | +6.2% |
| Profit before tax | 8.59 | 6.13 | 3.80 | 3.72 | 3.80 | 0.74 | 0.50 |
| Net profit | 6.39 | 4.15 | 3.30 | 2.81 | 2.81 | 0.54 | 0.36 |
| Net profit margin | +4.9% | +5.1% | +7.1% | +6.6% | +8.4% | +1.7% | +1.2% |
| EPS (₹) | 1.94 | 1.26 | 3.01 | 2.55 | 3.50 | 10.91 | 8.52 |
| Balance sheet | |||||||
| Total assets | 67.74 | 50.18 | 41.37 | 39.54 | 27.14 | 23.75 | 14.75 |
| Net worth | 45.87 | 39.46 | 35.58 | 32.27 | 11.29 | 6.88 | 5.37 |
| Total debt | 21.73 | 10.59 | 5.69 | 7.18 | 15.85 | 16.82 | 9.33 |
| Cash & bank | 1.46 | 0.06 | 0.03 | 0.06 | 0.19 | 0.04 | 0.30 |
| Net working capital | 53.35 | 38.08 | 27.86 | 31.81 | 18.36 | 15.35 | 8.89 |
| Cash flow | |||||||
| Cash from operations | (4.33) | (3.56) | 8.36 | (9.07) | 2.32 | (5.87) | 3.21 |
| Cash from investing | (3.94) | 0.02 | (6.07) | 0.87 | (0.71) | (1.64) | (2.76) |
| Cash from financing | 9.10 | 3.54 | (2.31) | 8.07 | (1.46) | 7.25 | (0.19) |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 98.65 | 11.10 | 63.05 | 26.84 | 29.91 | 11.59 | 11.73 | 21.25 |
| Revenue growth (YoY) | +229.8% | -4.2% | +437.5% | +26.3% | -24.3% | +21.5% | - | - |
| Other income | 0.00 | 0.02 | 0.04 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
| Total expenses | 92.00 | 9.01 | 59.54 | 23.49 | 26.99 | 9.65 | 10.36 | 19.90 |
| EBITDA | 6.65 | 2.09 | 3.51 | 3.35 | 2.92 | 1.94 | 1.37 | 1.35 |
| EBITDA margin | +6.7% | +18.8% | +5.6% | +12.5% | +9.8% | +16.7% | +11.7% | +6.4% |
| Depreciation | 0.32 | 0.32 | 0.27 | 0.27 | 0.27 | 0.26 | 0.36 | 0.16 |
| Interest | 0.68 | 0.30 | 1.03 | 0.38 | 0.44 | 0.24 | 0.33 | 0.20 |
| Profit before tax | 5.65 | 1.49 | 2.25 | 2.71 | 2.22 | 1.44 | 0.68 | 0.99 |
| Tax | 1.42 | 0.38 | 0.59 | 0.68 | 0.24 | 0.69 | 0.60 | 0.25 |
Financial Statements
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 98.65 | 11.10 | 63.05 | 26.84 | 29.91 | 11.59 | 11.73 | 21.25 |
| Revenue growth (YoY) | +229.8% | -4.2% | +437.5% | +26.3% | -24.3% | +21.5% | - | - |
| Other income | 0.00 | 0.02 | 0.04 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
| Total expenses | 92.00 | 9.01 | 59.54 | 23.49 | 26.99 | 9.65 | 10.36 | 19.90 |
| EBITDA | 6.65 | 2.09 | 3.51 | 3.35 | 2.92 | 1.94 | 1.37 | 1.35 |
| EBITDA margin | +6.7% | +18.8% | +5.6% | +12.5% | +9.8% | +16.7% | +11.7% | +6.4% |
| Depreciation | 0.32 | 0.32 | 0.27 | 0.27 | 0.27 | 0.26 | 0.36 | 0.16 |
| Interest | 0.68 | 0.30 | 1.03 | 0.38 | 0.44 | 0.24 | 0.33 | 0.20 |
| Profit before tax | 5.65 | 1.49 | 2.25 | 2.71 | 2.22 | 1.44 | 0.68 | 0.99 |
| Tax | 1.42 | 0.38 | 0.59 | 0.68 | 0.24 | 0.69 | 0.60 | 0.25 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 131 | 82.04 | 46.55 | 42.83 | 33.59 | 32.77 | 30.17 |
| Revenue growth | +60.1% | +76.2% | +8.7% | +27.5% | +2.5% | +8.6% | - |
| Other income | 0.07 | 0.01 | 0.52 | 1.64 | 0.89 | 0.09 | 0.03 |
| Total expenses | 120 | 73.85 | 42.00 | 38.90 | 28.23 | 30.61 | 28.30 |
| Employee cost | 0.00 | 1.01 | 2.01 | 1.83 | 1.43 | 0.98 | 1.25 |
| EBITDA | 11.71 | 8.19 | 4.55 | 3.93 | 5.36 | 2.16 | 1.87 |
| EBITDA margin | +8.9% | +10.0% | +9.8% | +9.2% | +16.0% | +6.6% | +6.2% |
| Depreciation | 1.08 | 0.99 | 0.44 | 0.43 | 0.37 | 0.28 | 0.24 |
| Interest | 2.11 | 1.08 | 0.83 | 1.42 | 2.08 | 1.23 | 1.16 |
| Profit before tax | 8.59 | 6.13 | 3.80 | 3.72 | 3.80 | 0.74 | 0.50 |
| Tax | 2.20 | 1.98 | 0.50 | 0.91 | 0.99 | 0.20 | 0.14 |
| Net profit | 6.39 | 4.15 | 3.30 | 2.81 | 2.81 | 0.54 | 0.36 |
| Net profit margin | +4.9% | +5.1% | +7.1% | +6.6% | +8.4% | +1.7% | +1.2% |
| EPS (₹) | 1.94 | 1.26 | 3.01 | 2.55 | 3.50 | 10.91 | 8.52 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 33.00 | 33.00 | 11.00 | 11.00 | 8.02 | 0.50 | 0.42 |
| Reserves & surplus | 12.87 | 6.46 | 24.58 | 21.27 | 3.27 | 6.38 | 4.95 |
| Shareholders' funds (net worth) | 45.87 | 39.46 | 35.58 | 32.27 | 11.29 | 6.88 | 5.37 |
| Secured loans | 21.18 | 10.19 | 5.69 | 7.18 | 13.53 | 12.91 | 5.87 |
| Unsecured loans | 0.55 | 0.40 | 0.00 | 0.00 | 2.32 | 3.91 | 3.46 |
| Total debt | 21.73 | 10.59 | 5.69 | 7.18 | 15.85 | 16.82 | 9.33 |
| Total liabilities | 67.74 | 50.18 | 41.37 | 39.54 | 27.14 | 23.75 | 14.75 |
| Assets | |||||||
| Gross block | 17.21 | 13.83 | 13.08 | 8.92 | 8.81 | 7.79 | 6.06 |
| Net block | 14.54 | 12.24 | 12.48 | 6.80 | 7.13 | 6.51 | 5.05 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 34.55 | 23.24 | 15.83 | 12.72 | 14.96 | 5.74 | 3.75 |
| Sundry debtors | 53.26 | 34.95 | 25.15 | 22.48 | 19.80 | 11.81 | 12.66 |
| Cash & bank balances | 1.46 | 0.06 | 0.03 | 0.06 | 0.19 | 0.04 | 0.30 |
| Loans & advances | 2.23 | 1.25 | 2.12 | 5.88 | 4.35 | 2.88 | 1.67 |
| Total current assets | 91.50 | 59.50 | 43.13 | 41.14 | 39.30 | 20.47 | 18.38 |
| Total current liabilities | 38.15 | 21.42 | 15.27 | 9.33 | 20.94 | 5.12 | 9.49 |
| Net working capital | 53.35 | 38.08 | 27.86 | 31.81 | 18.36 | 15.35 | 8.89 |
| Total assets | 67.74 | 50.18 | 41.37 | 39.54 | 27.14 | 23.75 | 14.75 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.03 | 0.03 | 0.06 | 0.19 | 0.04 | 0.30 | 0.03 |
| Net cash from operating activities | (4.33) | (3.56) | 8.36 | (9.07) | 2.32 | (5.87) | 3.21 |
| Net cash from investing activities | (3.94) | 0.02 | (6.07) | 0.87 | (0.71) | (1.64) | (2.76) |
| Net cash from financing activities | 9.10 | 3.54 | (2.31) | 8.07 | (1.46) | 7.25 | (0.19) |
| Net change in cash | 0.83 | 0.00 | (0.03) | (0.13) | 0.15 | (0.26) | 0.27 |
| Closing cash | 1.46 | 0.06 | 0.03 | 0.06 | 0.19 | 0.04 | 0.30 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +60.1% | +76.2% | +8.7% | +27.5% | +2.5% | +8.6% | - |
| EBITDA growth | +43.0% | +80.0% | +15.8% | -26.7% | +148.2% | +15.5% | - |
| PBT growth | +39.9% | +61.6% | +2.2% | -2.1% | +413.5% | +48.0% | +19.1% |
| Net income growth | +54.0% | +25.8% | +17.4% | 0.0% | +420.4% | +50.0% | - |
| Revenue CAGR (3Y) | +45.3% | +34.7% | +12.4% | +12.4% | +1.9% | - | - |
| EBITDA CAGR (3Y) | +43.9% | +15.2% | +28.2% | +28.1% | +59.5% | - | - |
| Profitability & leverage | |||||||
| Net income margin | +4.9% | +5.1% | +7.1% | +6.6% | +8.4% | +1.7% | +1.2% |
| Return on capital employed | +18.2% | +15.8% | +11.4% | +15.4% | +23.1% | +10.2% | +11.8% |
| Return on net worth | +15.0% | +11.1% | +9.8% | +12.9% | +30.9% | +8.8% | +6.9% |
| Debt / equity | 0.38 | 0.22 | 0.19 | 0.53 | 1.80 | 2.13 | 1.71 |
| Long-term debt / equity | 0.09 | 0.02 | 0.03 | 0.22 | 0.91 | 0.78 | 0.41 |
| Interest cover | 19.85 | 14.98 | 20.19 | 40.57 | 41.68 | 65.43 | 71.17 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 8.47 | 6.10 | 4.23 | 4.83 | 4.05 | 4.73 | 6.48 |
| Inventory turnover | 4.55 | 4.20 | 3.26 | 3.09 | 3.25 | 6.91 | 11.05 |
| Debtors turnover | 2.98 | 2.73 | 1.95 | 2.03 | 2.13 | 2.68 | 2.70 |
| EPS (₹) | 1.94 | 1.26 | 3.01 | 2.55 | 3.50 | 10.91 | 8.52 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 13.90 | 11.96 | 32.35 | 29.34 | 14.08 | 138.28 | 127.11 |
Web traffic of JFL LIFE SCIENCES
The website of JFL LIFE SCIENCES (jfllifesciences.com) receives about 1.1K visits a month.
- Monthly visits1.1K
▼ 28.3% vs previous month
Top companies in Traditional Health & Nutrition
3 companies that operate in the same segment as JFL LIFE SCIENCES (Traditional Health & Nutrition) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Oral solid drug delivery systems are manufactured and developed. | 1985 | Mumbai, Maharashtra, India | USD 42.49 M | USD 72.52 M | 1,115 | |
Generic, semi-solid, and liquid dosage forms are manufactured. | 1990 | Bengaluru, Karnataka, India | USD 508.93 M | 4,050 | ||
Specialty generic pharmaceuticals and APIs are manufactured and marketed. | 1983 | Mumbai, Maharashtra, India | USD 6.44 B | 19,801 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Jfl Life Sciences
Complete news archive for JFL LIFE SCIENCES
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about JFL LIFE SCIENCES
JFL LIFE SCIENCES was founded in 2011.
JFL LIFE SCIENCES is headquartered in Ahmedabad, India. It is registered at Ahmedabad, Gujarat, India.
JFL LIFE SCIENCES has 6 employees.
The primary company behind JFL LIFE SCIENCES, Jfl Life Sciences Limited, reported revenue of ₹131 Cr for FY 2026, up 60% year on year.
JFL Life Sciences was established in 2011 in Ahmedabad, India, within the life sciences sector. Pharmaceutical manufacturing operations are centered on general tablets, capsules, and dry powder injections. Production facilities are maintained in India to support these core activities. Leadership is provided by founder and director Smiral Patel, with focus placed on standard formulations for the industry.
JFL LIFE SCIENCES offers Dry Powder Injections and Tablets and Capsules.
Yes, JFL LIFE SCIENCES is publicly traded on NSE under the ticker symbol JFLLIFE.
JFL LIFE SCIENCES operates through Jfl Life Sciences Limited.
The legal entities of JFL LIFE SCIENCES currently have 7 directors, including Bhavna Basantbhai Shah, Manishkumar Jasvantlal Patel, Sonu Lalitkumar Jain and others.